Prof. Ernest Giralt
Co-Founder & Chairman
Professor Giralt is currently Professor of Organic Chemistry at the University of Barcelona and Coordinator of the Chemistry and Molecular Pharmacology Programme at the IRB Barcelona. He is an internationally renowned scientist in the field of peptide synthesis, medicinal chemistry, structure determination and NMR (Nuclear Magnetic Resonance). Besides, Prof. Giralt is an expert on the design of therapeutic ligands for interaction with protein surfaces. He is one of the founding members of the European Peptide Society, as well as editor of The Journal of Peptide Science. He is an inventor with 10 patents, and he serves on the advisory boards of a number of pharma and biotech companies.
Prof. Javier Meana
Advisor on Pharmacology and Schizophrenia
Professor Meana is Professor of Pharmacology at the University of the Basque Country, leader of the Neuropsychopharmacology Research Group at the same centre, and head of a research group at the Spanish Centre for Biomedical Research in Mental Health (CIBERSAM), which focuses on translational activities. He has published more than 200 papers and he is a member of several international scientific societies and committees. In 2009, he received the Research Award of the Spanish Society of Biological Psychiatry.
Advisor on Business Development and Licensing Strategy
Pascal Nizet specialises in international business development and has over 20 years’ experience in companies in the life and health sciences sector. In 2008, he founded the pharmaceutical consulting company Pharmaphenix, which focuses on emerging markets in Latin America and Asia. Previously, he worked at Almirall as Area Manager and International Marketing Manager, and as Marketing Strategic Director at Laboratorios Rubió. He is a member of the board of the biotech Bionure.
CMC and DDS expert
Roland Chérif-Cheikh is an expert in drug delivery system, Founder and General Manager of ASCIL Biopharm, an innovative drug delivery company expert in biotech CMC & Med Tech projects. He has a more than 30 years of industrial experience in the research and development of new medicines mostly based on peptides actives. He is one of the pioneers in the field of parenteral peptides drug delivery and at the root of disruptive therapeutic innovations. He worked in R&D projects that represent today a market of billions of euros. Prior to founding ASCIL, he was VP Formulation Innovation for Ipsen, leading the biotech DDS & Medtech innovation of the group during more than 25 years. He is inventor on over 500 granted and pending patents.